Eplivanserin/volinanserin

Eplivanserin/volinanserin is a combination of eplivanserin and volinanserin, both of which are selective serotonin 5-HT2A receptor antagonists, which is under development for the treatment of psychiatric and neurological disorders. One of its indications is to block the hallucinogenic effects of serotonergic psychedelics, for instance to abort psychedelic experiences early or to allow for take-home medications without hallucinations but with potentially retained therapeutic benefits.

Source: Wikipedia — Eplivanserin/volinanserin (CC BY-SA 4.0)